- Home
- PMM vs ATAI Comparison
PMM vs ATAI Comparison
Compare PMM & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | ATAI |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | 99 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.9M | 1.6B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | PMM | ATAI |
|---|---|---|
| Price | $6.16 | $4.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 105.8K | ★ 4.3M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.83 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $5.77 | $2.00 |
| 52 Week High | $6.52 | $6.73 |
Technical Indicators
Market Signals| Indicator | PMM | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 56.39 |
| Support Level | $6.06 | $4.23 |
| Resistance Level | $6.19 | $4.58 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 33.30 | 71.90 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.